Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX Stock Report

Market Cap: US$4.5b

Crinetics Pharmaceuticals Valuation

Is CRNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRNX ($47.9) is trading below our estimate of fair value ($115.51)

Significantly Below Fair Value: CRNX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRNX?

Key metric: As CRNX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CRNX. This is calculated by dividing CRNX's market cap by their current book value.
What is CRNX's PB Ratio?
PB Ratio4.2x
BookUS$1.07b
Market CapUS$4.55b

Price to Book Ratio vs Peers

How does CRNX's PB Ratio compare to its peers?

The above table shows the PB ratio for CRNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.7x
BLTE Belite Bio
19x68.54%US$5.2b
LGND Ligand Pharmaceuticals
3.8x19.72%US$3.7b
PBH Prestige Consumer Healthcare
1.6x5.09%US$2.9b
SUPN Supernus Pharmaceuticals
2.5x58.53%US$2.6b
CRNX Crinetics Pharmaceuticals
4.2x32.64%US$4.5b

Price-To-Book vs Peers: CRNX is good value based on its Price-To-Book Ratio (4.2x) compared to the peer average (6.7x).

Price to Book Ratio vs Industry

How does CRNX's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

22 CompaniesPrice / BookEstimated GrowthMarket Cap
PLRX Pliant Therapeutics
0.4x3.08%US$77.43m
HYPD Hyperion DeFi
0.4xn/aUS$26.93m
CTXR Citius Pharmaceuticals
0.3x51.66%US$22.17m
VYNE VYNE Therapeutics
0.4x-30.76%US$12.54m
CRNX 4.2xIndustry Avg. 2.5xNo. of Companies22PB01.63.24.86.48+
22 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CRNX is expensive based on its Price-To-Book Ratio (4.2x) compared to the US Pharmaceuticals industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is CRNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRNX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CRNX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRNX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$47.90
US$80.21
+67.46%
20.23%US$108.00US$45.00n/a14
Dec ’26US$45.25
US$80.21
+77.27%
20.23%US$108.00US$45.00n/a14
Nov ’26US$43.50
US$80.27
+84.52%
28.78%US$143.00US$40.00n/a15
Oct ’26US$41.61
US$80.27
+92.90%
28.78%US$143.00US$40.00n/a15
Sep ’26US$30.99
US$69.38
+123.86%
22.60%US$97.00US$35.00n/a16
Aug ’26US$27.84
US$70.38
+152.78%
22.17%US$97.00US$36.00n/a16
Jul ’26US$28.43
US$72.67
+155.60%
18.23%US$97.00US$53.00n/a15
Jun ’26US$30.51
US$72.67
+138.17%
18.23%US$97.00US$53.00n/a15
May ’26US$33.52
US$75.36
+124.81%
18.19%US$100.00US$53.00n/a14
Apr ’26US$30.62
US$75.36
+146.10%
18.19%US$100.00US$53.00n/a14
Mar ’26US$35.78
US$75.64
+111.41%
17.54%US$100.00US$55.00n/a14
Feb ’26US$40.30
US$75.43
+87.17%
16.06%US$97.00US$55.00n/a14
Jan ’26US$51.13
US$75.07
+46.82%
15.56%US$97.00US$55.00n/a14
Dec ’25US$57.20
US$73.29
+28.12%
17.04%US$97.00US$54.00US$45.2514
Nov ’25US$56.69
US$70.07
+23.60%
18.34%US$97.00US$48.00US$43.5014
Oct ’25US$51.92
US$69.21
+33.31%
19.00%US$97.00US$48.00US$41.6114
Sep ’25US$53.06
US$69.21
+30.45%
19.00%US$97.00US$48.00US$30.9914
Aug ’25US$52.07
US$68.00
+30.59%
20.33%US$97.00US$48.00US$27.8414
Jul ’25US$46.07
US$67.50
+46.52%
21.39%US$97.00US$47.00US$28.4314
Jun ’25US$44.41
US$65.07
+46.52%
20.53%US$97.00US$47.00US$30.5114
May ’25US$45.05
US$56.86
+26.21%
16.72%US$80.00US$40.00US$33.5214
Apr ’25US$46.53
US$56.86
+22.19%
16.72%US$80.00US$40.00US$30.6214
Mar ’25US$46.03
US$51.23
+11.30%
16.26%US$65.00US$35.00US$35.7813
Feb ’25US$37.21
US$47.67
+28.10%
15.68%US$62.00US$35.00US$40.3012
Jan ’25US$35.58
US$47.27
+32.86%
17.52%US$62.00US$35.00US$51.1311
Dec ’24US$32.74
US$46.30
+41.42%
18.23%US$57.00US$33.00US$57.2010
US$80.21
Fair Value
40.3% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/10 15:18
End of Day Share Price 2025/12/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Crinetics Pharmaceuticals, Inc. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
David LebowitzCitigroup Inc